We need trustworthiness to engender public trust for #SARCoV2 vaccines. And far better representation of the Black community as participants in the clinical trials. This new @NEJM perspective maps it out nejm.org/doi/full/10.10… by Reuben Warren, @LachlanForrow and colleagues pic.twitter.com/mSUP8PoCPu

Without confidence of Black communities no covid vaccines can succeed in ending this pandemic. See NEJM article w Tuskegee colleagues calling for an urgent "Operation Build Trustworthiness" to match "Operation Warp Speed": nejm.org/doi/full/10.10… #OperationBuildTrustworthiness

Black people make up 13% of the U.S. population, they account for 21% of deaths from Covid-19 but only 3% of enrollees in vaccine trials. This threatens the validity and generalizability of the vaccine trial results.

“although Black people make up 13% of the U.S. population, they account for 21% of deaths from Covid-19 but only 3% of enrollees in vaccine trials. This problem threatens both the validity and the generalizability of the trial results...”

Trust needs to be earned and maintained, rather than expected. "Trustworthiness before Trust: COVID 19 Vaccine Trials and the Black Community"

Trustworthiness before Trust — Covid-19 Vaccine Trials and the Black Community | NEJM "Black people make up 13% of the U.S. population, they account for 21% of deaths from Covid-19 but only 3% of enrollees in vaccine trial"